##{"id":99257,"date":"2022-01-26T00:00:00","date_gmt":"2022-01-25T13:00:00","guid":{"rendered":"https:\/\/www.fnarena.com\/index.php\/2022\/01\/26\/kazia-therapeutics-to-participate-in-edison-groups-global-healthcare-open-house-virtual-conference\/"},"modified":"2022-01-26T00:00:00","modified_gmt":"2022-01-25T13:00:00","slug":"kazia-therapeutics-to-participate-in-edison-groups-global-healthcare-open-house-virtual-conference","status":"publish","type":"post","link":"https:\/\/staging.fnarena.com\/index.php\/2022\/01\/26\/kazia-therapeutics-to-participate-in-edison-groups-global-healthcare-open-house-virtual-conference\/","title":{"rendered":"KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP&#8217;S GLOBAL HEALTHCARE &#8216;OPEN HOUSE&#8217; VIRTUAL CONFERENCE"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/766762\/Kazia_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"xn-location\">SYDNEY<\/span>, <span class=\"xn-chron\">Jan. 25, 2022<\/span> \/PRNewswire\/ &#8212; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr <span class=\"xn-person\">James Garner<\/span>, will be speaking at the Edison Group &#8216;Open House&#8217; Event, to be held virtually from <span class=\"xn-chron\">25-27 January 2022<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>Kazia will be one of 33 leading healthcare companies to be featured at the three-day event, which is being held in association with London Stock Exchange, global law firm Taylor Wessing, and OpenExchange. Day one of the conference will feature businesses within pharmaceuticals and drug discovery, day two will focus on AI and technology in healthcare, while businesses adopting new approaches to hard-to-solve problems will round off the third day of the event.<\/p>\n<p>Content will be available to stream from <span class=\"xn-chron\">25 January 2022<\/span> on Edison&#8217;s website and OpenExchange.tv. Attendance is free and interested investors are encouraged to register for the event via the following link:<\/p>\n<p><a target=\"_blank\" href=\"https:\/\/www.edisongroup.com\/event\/edison-open-house-global-healthcare-2022\/\" rel=\"nofollow\">https:\/\/www.edisongroup.com\/event\/edison-open-house-global-healthcare-2022\/<\/a><\/p>\n<p>Kazia will be presenting on day two of the conference, and the company&#8217;s session will be available on demand on the conference website from <span class=\"xn-chron\">8am, GMT<\/span>, on Wednesday, <span class=\"xn-chron\">26 January 2022<\/span>, and will subsequently be posted on the company&#8217;s website.<\/p>\n<p><b>For More Information, Please Contact:-<\/b><\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tbody>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><i><u>In the United States:<\/u><\/i><\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Joe Green<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Edison Investor Relations<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\"><a target=\"_blank\" href=\"mailto:jgreen@edisongroup.com\" class=\"prnews_a\" rel=\"nofollow\">jgreen@edisongroup.com<\/a><\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Phone: +1 646-653-7030<\/span><\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><i><u>In Australia:<\/u><\/i><\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Jane Lowe<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">IR Department<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\"><a target=\"_blank\" href=\"mailto:jane.lowe@irdepartment.com.au\" class=\"prnews_a\" rel=\"nofollow\">jane.lowe@irdepartment.com.au<\/a><\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Phone: +61 411 117 774<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p><b>About Kazia Therapeutics Limited<\/b><\/p>\n<p>Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in <span class=\"xn-location\">Sydney, Australia<\/span>.<\/p>\n<p>Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K \/ Akt \/ mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in <span class=\"xn-chron\">January 2021<\/span>. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in <span class=\"xn-chron\">February 2018<\/span>, and Fast Track Designation for glioblastoma by the US FDA in <span class=\"xn-chron\">August 2020<\/span>. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in <span class=\"xn-chron\">August 2020<\/span>.<\/p>\n<p>Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in <span class=\"xn-chron\">April 2021<\/span>. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in <span class=\"xn-chron\">November 2021<\/span>.<\/p>\n<p>For more information, please visit <a target=\"_blank\" href=\"http:\/\/www.kaziatherapeutics.com\/\" rel=\"nofollow\">www.kaziatherapeutics.com<\/a> or follow us on Twitter @KaziaTx.<\/p>\n<p>This document was authorized for release to the ASX by <span class=\"xn-person\">James Garner<\/span>, Chief Executive Officer, Managing Director.<\/p>\n<p><b>About Edison Group<\/b><\/p>\n<p>Edison&#8217;s leading research and investor relations consultancy connects listed companies to the widest pool of global investors. By focusing on both the volume and quality of investors reached \u2013 across institutions, family offices, wealth managers and retail investors \u2013 Edison can create and gauge intent to purchase, even in the darkest pools of capital.<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.edisongroup.com\/\" rel=\"nofollow\">www.edisongroup.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">  <\/div>\n","protected":false},"excerpt":{"rendered":"<p>SYDNEY, Jan. 25, 2022 \/PRNewswire\/ &#8212; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[105],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/99257"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=99257"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/99257\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=99257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=99257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=99257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}